October 01, 2014 3:01 AM ET

Biotechnology

Company Overview of ARCA biopharma, Inc.

Company Overview

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

11080 CirclePoint Road

Suite 140

Westminster, CO 80020

United States

14 Employees

Phone:

720-940-2200

Key Executives for ARCA biopharma, Inc.

Co-Founder
Age: 69
Total Annual Compensation: $389.4K
Chief Financial Officer and Principal Accounting Officer
Age: 45
Total Annual Compensation: $338.8K
Senior Vice President
Age: 55
Total Annual Compensation: $323.6K
Compensation as of Fiscal Year 2013.

ARCA biopharma, Inc. Key Developments

ARCA biopharma, Inc. Announces Health Canada Acceptance of GENETIC-AF Clinical Trial Application

ARCA biopharma, Inc. announced that the company's Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in the fourth quarter of 2014. ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the United States. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted therapy for the prevention of atrial fibrillation. AF is a disorder in which the normally regular and coordinated contraction pattern of the heart's two small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF increases the risk of mortality and morbidity due to stroke, congestive heart failure and impaired quality of life. The approved therapies for the treatment or prevention AF have certain disadvantages in patients with heart failure and/or reduced left ventricular ejection fraction (HFREF) patients. GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL for prevention of symptomatic AF/atrial flutter in HFREF patients. ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company initiated the trial as a Phase 2B trial in approximately 200 patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.

ARCA biopharma, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM

ARCA biopharma, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.

ARCA biopharma, Inc. Elects Robert E. Conway as Chairman of the Board of Directors

ARCA biopharma, Inc. announced that Robert E. Conway has been elected Chairman of the company's Board of Directors. He serves on the Audit and Compensation Committees of the Board of Directors. Mr. Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries. Mr. Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999.

Similar Private Companies By Industry

Company Name Region
Center for Biocatalysis and Bioprocessing United States
Nymirum, Inc. United States
Biomerk, Inc. United States
Neuro Bioscience Inc. United States
Neose Technologies Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARCA biopharma, Inc., please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.